Myocardial Infarction Research
Myocardial infarction (MI) - more commonly referred to as a heart attack - is an acute event caused by the interruption of blood supply to regions of the heart, leading to myocardial necrosis. Infarction of a substantial area of the myocardium can disrupt normal conductance of the heart, leading to cardiac arrest.In the majority of cases, an MI is immediately preceded by the presence of an occlusive thrombus within a coronary artery, blocking blood flow to the downstream tissue. The most common cause of an occlusive thrombus within a coronary artery is the rupture of an atherosclerotic plaque. However, the occlusion of a coronary artery may also result from coronary embolism. This can occur in patients following stent placement, angioplasty, and coronary artery bypass grafting.
Myocardial Infarction Research Products Targets
- Adenosine A2B Receptor (7)
- Adenosine A2A Receptor (11)
- Voltage-gated Sodium (NaV) Channel (30)
- Voltage-gated Potassium (KV) Channel (38)
- Voltage-gated Calcium Channel (CaV) (38)
- Cell Adhesion Molecule (21)
- Others (10)
- Cyclooxygenase (24)
- Epithelial Sodium Channel (3)
- STIM-Orai Channel (4)
- Ryanodine Receptor (6)
- Angiotensin-Converting Enzyme (8)
- IP3 Receptor (2)
- Adenosine A3 Receptor (8)
- Adenosine A1 Receptor (12)
- Acid-Sensing Ion Channel (3)
- Calcium-Activated Potassium (KCa) Channel (19)
- Inward Rectifier Potassium (Kir) Channel (21)
- NO donors and precursors (9)
- nNOS (5)
- iNOS (11)
- eNOS (1)
- Stem Cell Differentiation (54)
- Delta opioid receptor (16)
- Cathepsin (9)
- Adrenergic β3 Receptor (12)
- Adrenergic β2 Receptor (6)
- Adrenergic β1 Receptor (7)
- Prostanoid Receptor (24)
Products for Myocardial Infarction Research - Page 8
- Cat.No. Product Name Information/Activity
-
BCC3781
Flurbiprofen
Flurbiprofen is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity.
-
BCC7092
FR 122047 hydrochloride
130717-51-0
-
BCC4042
(S)-(+)-Ibuprofen
(S)-(+)-Ibuprofen is the S(+)-enantiomer of Ibuprofen that inhibits COX-1 and COX-2 activity with IC50s of 2.1 μM and 1.6 μM. (S)-(+)-Ibuprofen has analgesic, antiinflammatory and antipyretic effects.
-
BCC3794
Indomethacin
Indomethacin (Indometacin) is a potent and nonselective inhibitor of COX1 and COX2, with IC50s of 18 nM and 26 nM for human COX-1 and COX-2, respectively, in CHO cells.
-
BCC6490
Naproxen Sodium
Naproxen sodium is a COX-1 and COX-2 inhibitor with IC50s of 8.72 and 5.15 μM, respectively in cell assay.
-
BCC7944
NCX 4040
287118-97-2
-
BCC6219
NCX 466
1262956-64-8
-
BCC6857
NS 398
NS-398 is a non-steroidal an-inflammatory agent with analgesic and antipyretic effects, and selectively inhibits prostaglandin G/H synthase 2/cyclooxygenase 2 (COX-2) activity, with an IC50 of 3.8 μM, and has no effect on COX-1 at 100 μM.
-
BCC3841
Piroxicam
Piroxicam (CP-16171) is a non-steroidal anti-inflammatory drugs, acts as a COX inhibitor, with IC50s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively.
-
BCN5607
Resveratrol
Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator. Resveratrol is a potent pregnane X receptor (PXR) inhibitor.


